CJC-1295 + ipamorelin + BPC-157 frequency

This article is for educational and journalistic purposes only. It does not constitute medical advice. CJC-1295, ipamorelin and BPC-157 are not approved medicines in the EU, UK, or US. All three are prohibited under WADA anti-doping rules. PeptideMethods does not recommend, endorse, or facilitate the purchase of any peptide product.

The starting point: no validated schedule exists for the combination

The question of how often to inject these three peptides together does not have a clinically grounded answer. A 2026 review of injectable peptide therapy written specifically for orthopaedic and sports medicine physicians stated that for compounds in this class, including CJC-1295 and ipamorelin, ^[1]. BPC-157 sits in the same position: there is no completed Phase 2 or Phase 3 human trial for any of these three peptides and no regulatory agency has validated a dosing regimen for human use^[1].

That gap matters because each of the three peptides operates through a different mechanism, clears at a different rate, and has a different body of human evidence. Treating the combination as a single protocol question with a single frequency answer misrepresents how thin the underlying data actually are.

CJC-1295: half-life determines the frequency logic

CJC-1295 with DAC, the original ConjuChem compound, covalently binds plasma albumin through a maleimidopropionyl-lysine linker and has an estimated half-life of 5.8 to 8.1 days^[2]. In healthy adults, a single subcutaneous injection at 30 to 60 micrograms per kilogram elevated mean plasma GH concentrations 2 to 10 times above baseline for six or more days and raised IGF-1 by 1.5 to 3 times for 9 to 11 days. With once or twice weekly dosing, IGF-1 remained above baseline for up to 28 days in the same pharmacokinetic studies^[2]. A companion study found that pulsatile GH secretion was preserved during CJC-1295 administration, with basal GH levels elevated roughly 7.5-fold and pulse frequency unchanged^[3].

The version most online vendors actually sell is CJC-1295 without DAC, also labelled MOD-GRF(1-29). Without the albumin-binding linker, the half-life drops to roughly 30 minutes, similar to sermorelin. The pharmacokinetic data above was collected using the with-DAC compound: the frequency logic built on a 6 to 8 day half-life does not transfer to the short-acting version. Most forum dosing discussions do not clarify which version is being described, which is one reason the practical numbers circulate without a clear evidence base. Full detail on the two versions is on the CJC-1295 peptide page.

Ipamorelin: a short pulse at a separate receptor

Ipamorelin is a synthetic pentapeptide that works through the GHS-R receptor, the same ghrelin receptor, rather than the GHRH receptor that CJC-1295 acts on. The rationale for pairing them is that activating both receptor types produces a larger GH pulse than either alone. That dual-receptor argument is mechanistically plausible and is cited in the commentary literature, but it has not been tested in a controlled human trial^[1]. Ipamorelin's half-life is short, estimated in early pharmacokinetic work at around two hours, which is why online discussions describe it as dosed once or multiple times daily. Those frequency figures are not drawn from efficacy trials and they are not endorsed by any regulatory agency. The full ipamorelin evidence summary is on the ipamorelin peptide page. No FDA-approved human medicine containing ipamorelin exists^[4].

BPC-157: the weakest evidence of the three

BPC-157 is a 15-amino-acid synthetic peptide derived from a sequence in gastric juice protein. The literature on its effects is almost entirely preclinical. Most published animal studies administer the peptide intraperitoneally at 10 micrograms or 10 nanograms per kilogram, typically once daily for the duration of the experiment. Those intraperitoneal doses in rodents cannot be reliably converted to a subcutaneous injection schedule in humans because the pharmacokinetic data needed to make that conversion do not exist. The US Department of Defense's Operation Supplement Safety page states plainly that there is ^[5]. USADA describes the regulatory position as no known safe dose and no legal basis for compounding pharmacies to prepare it^[5]. Full detail on BPC-157 is on the peptide page.

What online frequency figures are based on

The numbers that circulate in forums, typically once or twice daily injections for ipamorelin and BPC-157, once or twice weekly for CJC-1295 with DAC, and daily or every-other-day for the no-DAC version, are extrapolations from animal study schedules and from the pharmacokinetic logic of each peptide's half-life. They are not drawn from controlled clinical trials in humans. Whether the combination at any of those frequencies is safe or effective in humans is a question the available evidence does not answer.

What we do not yet know

Several questions about this combination are genuinely open. Whether activating the GHRH receptor with CJC-1295 and the GHS-R receptor with ipamorelin simultaneously produces a GH response in humans that is larger than either alone has not been measured in a controlled trial. How BPC-157 interacts pharmacodynamically with GH-axis peptides is not characterised in any human study. What the chronic-use safety profile of any of these three peptides looks like over months or years, including effects on glucose regulation, IGF-1 trajectory, and the theorised oncologic concern that applies to all GH-axis agents, remains unknown because long-duration human data do not exist.

Practical context

If you are researching this combination, the evidence base for a validated frequency is absent at every level: no approved human medicine, no completed efficacy trial, no regulatory-endorsed schedule. The pharmacokinetic argument for the with-DAC CJC-1295 frequency comes from two small 2006 studies; the rest is extrapolation. Any decision about whether to use these peptides, and at what frequency, is a conversation for a clinician who can review your individual situation and the applicable jurisdiction-specific legal position. Country-specific regulatory detail is on the CJC-1295, ipamorelin, and BPC-157 peptide pages.